Evolent Health (EVH) Q3 2026 Earnings Call Transcript
Evolent Health (EVH) reiterated its full-year revenue guidance of $2.6B-$2.7B and raised Adjusted EBITDA guidance to $130M-$135M. The company reported customer contract renewals and expansions, including a 4-year renewal with its largest Surgical Management customer and expansions in oncology and specialty services.
How this was made
The 30-second read
Why it matters
The disclosed guidance and operational updates provide fresh data for valuation models and may shift analyst expectations.
Market read
Guidance and AI product rollout could influence sector sentiment and valuation multiples for health‑tech peers.
What to watch
Potential regulatory scrutiny of AI‑driven authorization tools could temper upside.
Background
Evolent Health outlined contract renewals, expansion deals, and AI platform progress during its Q3 2026 earnings call.
Ticker impact
Q3 2026 earnings call disclosed full-year revenue guidance of $2.6‑$2.7 B and adjusted EBITDA guidance of $130‑$135 M.
neutral to slight upside as investors price in higher EBITDA guidance.
Guidance is new information; no prior guidance was public, so the market will adjust pricing accordingly.
Market effects
Positive for specialty health‑services sector as the guidance suggests continued growth in oncology and AI‑driven utilization management.
U.S. healthcare services investors may see modest re‑rating.
Limited; primarily affects U.S. listed health‑tech stocks.
Counterpoint
If the guidance is already priced in, the stock could face pressure on any short‑term earnings miss.
Key entities
- companyEvolent Health
U.S. health‑services provider (NASDAQ:EVH).
- partnerAmerican Oncology Network
Collaborator on new cancer‑care model.
